EU approval urged for Roche’s Columvi combo in large B-cell lymphoma

 

• Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2
• DLBCL—an aggressive disease with a high risk of progression—remains an area of high unmet need, especially for treatments that can be initiated soon after the cancer returns
• If approved, this off-the-shelf, fixed-duration Columvi combination will be the first bispecific antibody regimen available for patients with DLBCL following relapse
• https://www.roche.com/media/releases/med-cor-2025-02-28